------------------------------------------------------------
[link removed]


** HIV Prevention and Equity in 2022 & Beyond
------------------------------------------------------------
Dear Advocates, Partners and Supporters,

This year was an incredible one of reflection, engagement, opportunity, and action. More than 40 years into the HIV epidemic – and in the midst of multiple other pandemics and persistent inequities – AVAC and its partners continue to reshape, reimagine and fight for effective HIV prevention.

We began 2022 with a new strategy ([link removed]) reflecting an evolving field and critical opportunities for HIV prevention and for global health:
* Research is accelerating, with more options available than ever before. But progress toward crucial targets has been far too slow, and these biomedical options are not yet real choices for the people who need them.
* COVID accelerated science, but significant gaps in access underscored the necessity for smart, equitable, and people-centered pandemic preparedness, prevention AND response.
* And a global movement for social justice continues to demand that we all reexamine critical questions of equity, including health equity.

As we close out the year, we’ve been asking ourselves, how have we done? And the answer, we hope, lays the foundation for bold action in 2023 and beyond.

Thanks to an incredible partnership network and committed donors and collaborators, I am proud to say that we’ve made significant progress. But, as Tony Fauci reminded us all last month when he and I had a chance to chat about history AND the future ([link removed]) , “much accomplished; much more to do.”

In all that we do at AVAC, we keep three aims in mind. Track and translate the science so the research enterprise and the communities who need prevention most are working hand in hand. Advocate for evidence-based, high-impact, community-centered programs, products and policies. And catalyze the relationships, partnerships, coalitions, advocacy agendas, joint commitments and action plans that get it all done.

Here’s a look at just some of the work we’ve done to advance all three in 2022.

We served as a bridge between the scientific field and communities where research happens.
* Published new evidence on a wide range of critical topics:
+ Correlations Between Oral Pre-Exposure Prophylaxis (PrEP) Initiations and Policies that Enable the Use of PrEP to Address HIV Globally ([link removed]) in PLOS
+ JIAS Viewpoint on ([link removed]) HIV vaccines in 2022: where to from here? ([link removed])
+ Catalyzing action on HIV/SRH integration: lessons from Kenya, Malawi, and Zimbabwe to spur investment ([link removed]) in Global Health Action
+ "It's Almost as if Stakeholder Engagement is the Annoying 'Have-to-do'…": ([link removed]) Can Ethics Review Help Address the "3 Ts" of Tokenism, Toxicity, and Tailoring in Stakeholder Engagement? ([link removed]) in the Journal of Empirical Research on Human Research Ethics
+ Safety data needed for concurrent use of ARV-based PrEP ([link removed](22)00256-9/fulltext) in Lancet HIV
* Convened critical ([link removed]) conversations to reframe and re-energize the search for an HIV vaccine ([link removed]) ; created a snapshot of Phase 1 mRNA HIV Vaccine Trials ([link removed]) that are underway and a backgrounder on experimental medicine vaccine trials (EMVTs) ([link removed]) that are driving the field forward.
* Spoke with advocates and global leaders on our PxPulse podcasts ([link removed]) about all forms of HIV prevention and what needs to happen next to ensure equitable access.
* Redesigned PrEPWatch.org ([link removed]) , a one-stop clearinghouse for the latest PrEP data on implementation and uptake, resources, and information on PrEP policies, programs and products, approved and in development.
* Created STIWatch.org ([link removed]) , the first and only resource on all things STI vaccine development.
* Tracked and translated new developments: created and shared more than 17 ([link removed]) accessible, up-to-date resources ([link removed]) on the full spectrum of biomedical HIV prevention products from research to rollout and real-time analysis of emerging developments.


We deepened our investment in supporting the next generation of skilled and informed advocates with the belief that advocacy and action must be founded on principles of power-sharing.
* Developed and continuously track our Plan for Accelerating Access and Introduction of Injectable CAB for PrEP ([link removed]) to ensure time is not wasted and opportunity is not squandered, and importantly, that civil society plays a meaningful role.
* Supported ([link removed]) the ([link removed]) African Women’s HIV Prevention Accountability Board ([link removed]) and our CASPR ([link removed]) and COMPASS ([link removed]) partners in meeting with global leaders, including Winnie Byanyima of UNAIDS, Amb. John Nkengasong of PEPFAR and Atul Gawande and Han Kang of USAID, to make the urgent case for faster and more equitable access to both the dapivirine vaginal ring ([link removed]) (DVR) and injectable cabotegravir ([link removed]) – and to listening to and engaging with civil society before making decisions.
* Welcomed the 12th class of the flagship Fellows Program with 8 new Advocacy Fellows ([link removed]) working on access to the DVR, U=U campaigns, and integrating SRH with HIV services.
* Established C ([link removed]) ureROAR ([link removed]) to support a cadre of advocates to gain knowledge in the science and process of cure research, and to develop an advocacy agenda to ethically advance cure research.
* Introduced T ([link removed]) he ([link removed]) Choice Agenda (TCA) ([link removed]) , a global forum for advocacy on HIV prevention, with agenda-setting conversations, deep-dive webinars ([link removed]) on key issues in the field and moderated passionate, highly-informed discussions ([link removed]) with 1,000 advocates and experts across the field.
* Launched an advocacy campaign with PrEP4All and other partners to ensure the US National PrEP Program reaches those who need prevention most – with a huge year-end victory this week when the US Congress included as part of its fiscal year 2023 budget ([link removed]) a call for the Centers for Disease Control and Prevention (CDC) to expand equitable national PrEP access in order to end the HIV epidemic!


We expanded our work to cultivate and sustain dynamic partnerships that set a bold and innovative agenda for HIV prevention.
* Launched The Coalition to Accelerate Access to Long-Acting PrEP ([link removed]) , a new initiative to ensure an accelerated, equitable, sustainable and collaborative approach to making longer-acting PrEP options accessible as quickly and as equitably as possible.
* Co-hosted the first Africa Health R&D Week ([link removed]) and launched the Domestic Resource Mobilization (DRM) Learning ([link removed]) Collaborativ ([link removed]) e ([link removed]) .
* Joined a wide range of partners in urging a comprehensive approach to Pandemic Preparedness, Prevention and Response ([link removed]) , outlining a funding agenda for the Pandemic Fund ([link removed]) and articulating key needs for future global health governance ([link removed]) .
* Hosted 20+ virtual and in-person think tanks and consultations to update and gather feedback on the latest developments related to the D ([link removed]) ual Prevention Pill ( ([link removed]) DPP) ([link removed]) market introduction, injectable CAB for PrEP ([link removed]) , and the MATRIX pipeline ([link removed]) of new HIV prevention and multipurpose prevention options.
* Hosted with Wits RHI ([link removed]) and CASPR ([link removed]) a GPP Symposium ([link removed]) exploring innovation in Good Participatory Practice (GPP) and strategizing for expansion of GPP in 2023.
* Convened 3,000+ participants on 28 webinars ([link removed]) to explore issues key to the future of the AIDS response, HIV prevention and global health equity.



Yes, together we’ve been able to do so much this year. But there remains a long, unfinished agenda for all of us in 2023 and beyond, that no one organization can address alone. The challenges ahead can only be defeated by building global solidarity, sharing responsibility and accountability, and mobilizing a response that leaves no one behind.

Thank you to all of our partners, AVAC staff, board, donors, and the remarkable individuals and organizations around the world who allow us to continue this critical work as part of a comprehensive and integrated pathway to global health equity.

In solidarity and with enormous gratitude,
Mitchell Warren and all of us at AVAC

P.S. We are grateful for all forms of support and partnership. If you can, please do consider a financial contribution to AVAC ([link removed]) to help keep this work moving, together.

============================================================
Forward This Issue Do you know someone who might be interested in receiving this newsletter?
** Forward > ([link removed])

Unsubscribe You're receiving this because you signed up for our newsletter. Not interested any longer?
** Unsubscribe > ([link removed])

Contact Us T: +1 212 796 6423
E: ** [email protected] (mailto:[email protected])
W: ** www.avac.org ([link removed])
** ([link removed])
** ([link removed])
** ([link removed])